Retatrutid vs. CagriSema
Die Zukunft der Gewichtsabnahme im Vergleich (2026)
Ein Vergleich der kommenden Giganten: Retatrutid (GIP/GLP-1/Glucagon) gegen CagriSema (Semaglutid/Cagrilintid).
Retatrutid vs. CagriSema: Auf einen Blick
- ✓Triple-Agonist: GIP + GLP-1 + Glucagon
- ✓Glucagon steigert den Energieverbrauch
- ✓~24 % Gewichtsverlust in Phase 2
- ✓In Entwicklung durch Eli Lilly
- ✓Kombination: Cagrilintid (Amylin) + Semaglutid (GLP-1)
- ✓Duale Sättigungswege
- ✓~22 % Gewichtsverlust in Phase 2
- ✓In Entwicklung durch Novo Nordisk
Detailed Comparison
| Feature | Retatrutide | Cagrisema |
|---|---|---|
| Mechanism | Triple GIP/GLP-1/glucagon receptor agonist | Amylin/GLP-1 combinationBest |
| Dosing | 1-12 mg SC weekly (phase 2 doses) | Cagrilintide 2.4 mg + semaglutide 2.4 mg SC weekly |
| Administration | Subcutaneous injection weekly | Subcutaneous injection weekly |
| Half-life | ~6 days | Cagrilintide ~7 days; semaglutide ~7 days |
| FDA Status | Not FDA-approved — phase 3 clinical trials | Not FDA-approved — phase 3 clinical trials |
| Key Trial | Jastreboff AM et al. NEJM 2023 — phase 2 obesity trial | Frias JP et al. Lancet 2023 — phase 2 combination trial |
| Side Effects | Nausea, diarrhea, vomiting, constipation (similar to other incretins) | GI effects similar to semaglutide; injection site reactions |
Which Should You Choose?
Retatrutide (triple gip/glp-1/glucagon receptor agonist) and CagriSema (Cagrilintide + Semaglutide) (amylin/glp-1 combination) serve different clinical roles despite both being in the Triple incretin agonist space. Retatrutide first triple incretin agonist targeting gip, glp-1, and glucagon receptors. CagriSema (Cagrilintide + Semaglutide) fixed-dose combination of cagrilintide (long-acting amylin analogue) and semaglutide (glp-1 agonist) that targets two satiety pathways for enhanced weight loss.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Making an Informed Choice Between Retatrutide and Cagrisema
Choosing between Retatrutide and Cagrisema depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Retatrutide and Cagrisema is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Retatrutide vs Cagrisema: Häufig gestellte Fragen
Beide befinden sich in Phase-3-Studien. Eine Zulassung wird für 2025/2026 erwartet.
Retatrutide oder Cagrisema in Shotlee tracken
Kostenloses Dosis-Tracking, Protokollierung von Nebenwirkungen und Ergebnisvergleich für jedes Medikamentenprotokoll.